Ert Pompe denied as not medically necessary by AmeriHealth Caritas?

Confirmed enzyme assay + genetic testing. Specialist Rx (geneticist or metabolic).

EPSDT for under-21 overrides state PDL limits. Orphan Drug Act + FDA approval rebut 'experimental' label. Site-of-care: home infusion appropriate for stable patients per manufacturer REMS.

## Why AmeriHealth Caritas Denies ERT for Pompe Disease on Medical-Necessity Grounds

AmeriHealth Caritas's medical-necessity criteria for enzyme replacement therapy in Pompe disease typically require documented confirmation of the diagnosis, evidence of active disease that would benefit from treatment, appropriate specialist oversight, and in some cases evidence of baseline functional impairment. Denials commonly occur when the authorization request does not include sufficient diagnostic documentation, when disease severity is not adequately quantified in the submitted records, or when the treating provider's notes do not explicitly address each criterion in AmeriHealth Caritas's coverage policy.

For both infantile-onset and late-onset Pompe disease, ERT is the only approved disease-modifying therapy, and treatment delays can result in irreversible cardiorespiratory and musculoskeletal deterioration — facts that are critical to include in any appeal.

## Federal Appeal Rights

For commercial AmeriHealth Caritas plans, ACA Section 2719 and ERISA Section 503 provide the right to internal appeal and independent external review. For Medicaid/CHIP enrollees (AmeriHealth Caritas is primarily a Medicaid managed care organization), state Medicaid appeal regulations govern the process, including the right to a state fair hearing before an administrative law judge — which is separate from the managed care organization's internal process. External review timelines for commercial plans are generally within 4 months. Expedited review should be requested for cases involving active respiratory compromise or cardiac involvement.

## Appeal Process and Timeline

1. Obtain the denial rationale — request the specific clinical criteria AmeriHealth Caritas found unmet, in writing. 2. Internal appeal — submit a comprehensive response to each unmet criterion. For Medicaid plans, also request a state fair hearing simultaneously if the plan's timeline permits concurrent filing. 3. Peer-to-peer review — the treating metabolic specialist should request a clinical peer-to-peer call with AmeriHealth Caritas's medical reviewer. 4. External review or state fair hearing — after internal exhaustion, pursue the appropriate external process for your plan type.

## Documentation to Gather

• Confirmed Pompe disease diagnosis: GAA gene variant sequencing results and/or lysosomal acid alpha-glucosidase enzyme activity assay from an accredited laboratory.
• Disease onset and type: documentation classifying the patient as infantile-onset or late-onset, as the clinical presentation and urgency differ.
• Functional status and progression: pulmonary function test results, motor function assessments, and echocardiogram (if infantile-onset) — without citing specific cutoff numbers, but documenting the patient's actual values and the treating clinician's interpretation.
• Specialist oversight: notes from a metabolic disease specialist, neuromuscular specialist, or genetics clinic confirming active management.
• Prescriber medical-necessity letter: explicitly addressing each criterion in AmeriHealth Caritas's coverage policy for ERT in Pompe disease, with citations to the FDA-approved prescribing label and the applicable specialist-society clinical guidelines.

## Criteria-Mapping Structure

Retrieve AmeriHealth Caritas's coverage policy for ERT in Pompe disease from the denial letter or the AmeriHealth Caritas provider policy library. List every criterion. For each: cite the exact diagnostic result, clinical note, or test value from the patient's chart. Cross-reference with the FDA-approved prescribing label's eligibility language. Present this as a numbered table — criterion, policy source, chart evidence — so the reviewer can confirm each item at a glance.